MediWound (NASDAQ:MDWD) Share Price Crosses Below 200-Day Moving Average – Here’s What Happened

MediWound Ltd. (NASDAQ:MDWD) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $17.65 and traded as low as $16.25. MediWound shares last traded at $16.93, with a volume of 81,062 shares changing hands.

Analyst Ratings Changes

Several analysts have issued reports on MDWD shares. Craig Hallum started coverage on MediWound in a research note on Friday, February 28th. They issued a “buy” rating and a $39.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of MediWound in a research note on Friday, January 10th.

MediWound Stock Performance

The company has a market cap of $182.61 million, a P/E ratio of -5.84 and a beta of 0.82. The business has a 50 day moving average price of $18.06 and a two-hundred day moving average price of $17.64.

Institutional Trading of MediWound

A number of institutional investors have recently made changes to their positions in MDWD. Investor AB bought a new stake in MediWound during the 3rd quarter valued at $15,750,000. Yelin Lapidot Holdings Management Ltd. increased its position in shares of MediWound by 13.4% in the fourth quarter. Yelin Lapidot Holdings Management Ltd. now owns 851,361 shares of the biopharmaceutical company’s stock valued at $15,154,000 after acquiring an additional 100,618 shares during the period. ARK Investment Management LLC bought a new position in shares of MediWound during the third quarter valued at about $1,806,000. Northern Trust Corp boosted its holdings in shares of MediWound by 94.6% during the fourth quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company’s stock worth $2,577,000 after purchasing an additional 70,367 shares during the period. Finally, State Street Corp grew its stake in shares of MediWound by 219.6% in the third quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock worth $1,197,000 after purchasing an additional 45,529 shares during the last quarter. Hedge funds and other institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.